Abstract
Review question/objective The objective of this review is to present the best available evidence related to allied health therapy in the symptomatic management of progressive supranuclear palsy (PSP). More specifically, the review question to be addressed is: Review question/objective • What are effective physiotherapy, occupational therapy and speech therapy techniques used in the symptomatic management of PSP? Background Progressive supranuclear palsy, or sometimes known as Steele-Richardson-Olsewski syndrome, is a rapidly degenerative neurological disorder. The average age of onset is 60-65 years with a life expectancy of six to seven years following diagnosis.1 The main symptoms of PSP typically include vertical gaze palsy (difficulty looking up or down), postural imbalance and falls, dysphagia (difficulty eating or drinking) and/or dysarthria (speech disorder).2 Progressive supranuclear palsy belongs to the class of neurodegenerative conditions called tauopathies. Aggregation of the protein tau in neurons can lead to damage in both cortical and subcortical areas of the brain.3 Background Progressive supranuclear palsy is a severe disorder that is under recognized and underdiagnosed.4 It is an insidious condition with devastating impacts on individuals, their families, and the health resources of the broader community.5 This review will focus solely on PSP; however, in order to understand this seemingly obscure condition, it is important to first discuss the class of neurological conditions to which it belongs and the trends in prevalence of these conditions. Background Progressive supranuclear palsy is a Parkinsonian condition, more specifically an atypical Parkinsonian condition. Parkinsonian conditions are a class of neurological disorders characterized by parkinsonism type symptoms such as slowness of movement, difficulty initiating movement, and rigidity with or without resting tremor.6 Parkinson's disease is the most common type. There is also a collection of conditions that may initially present similar symptoms to Parkinson's disease, but as the disease progresses they evolve in a critically different way to Parkinson's disease.6 These conditions have been named atypical Parkinsonian or Parkinson's plus syndromes. As mentioned, PSP is one type of atypical Parkinsonian conditions, others include multiple system strophy (MSA) and dementia with Lewy bodies.6 The key differences between Parkinson's disease and atypical Parkinsonian conditions have been summarized in Table 1 taken from Litvan.6 Background The similarities and differences of Parkinson's disease and atypical Parkinsonian conditions begin to illustrate the complexities of PSP. People with Parkinson's disease and PSP all present with parkinsonism symptoms. Unlike most presentations of typical Parkinson's disease, people with PSP experience rapid progression of their disorder, early instability or falls, early dysphagia and/or dysarthria without the alleviating benefits of levodopa6 or an alternative effective medication.7 They experience an economic burden of disease high above that reported for Parkinson's disease,5 and may remain undiagnosed for approximately half of the natural history of their disease.8 Background As mentioned previously, PSP is a seemingly obscure disorder. To appreciate the true scale of the disorder it is necessary to explore the difficulties in defining, diagnosing and therefore ascertaining the actual prevalence of PSP. These difficulties, against the backdrop of a recent generalized trend of increasing prevalence of all neurodegenerative disorders14, paint a different picture. Background It is interesting to consider that the prevalence of PSP has been estimated to be 6.5 per 100,000,8 similar to the prevalence of motor neuron disease (MND),1 a far more well-known neurodegenerative disorder. Six of the seven states in Australia have their own MND Association, while there is only one PSP Association.9 The difference in the level of services and awareness of two conditions with a similar prevalence may be related to how easily they can be defined. Historically, MND was more readily accepted as a separate morbid entity due to a distinctive clinical and pathological presentation in comparison to PSP.1 Background Diagnosis of PSP continues to be a complex process, as demonstrated by a 41% misdiagnosis rate.8 Progressive supranuclear palsy is difficult to discern from Parkinson's disease due to an overlap in presenting symptoms.6,8 It is also commonly misdiagnosed as stroke.8 Autopsy continues to be the gold standard in the diagnosis of PSP.7 The National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP (SPSP) have developed criteria to assist the clinical diagnosis of PSP10 which has been summarized in Table 2. Clinical diagnosis utilizing the NINDS-SPSP criteria is frequently used in studies researching PSP, presumably due to the difficulties obtaining autopsy results from participants. A recent study11 comparing the diagnostic accuracy of NINDS-SPSP against the gold standard of autopsy identified that NINDS-SPSP's probable criteria is appropriate for recruitment into clinical trials where an early and specific diagnosis is important.11 In the case of routine care where high sensitivity is crucial, a combination of NINDS-SPSP's possible and probable criteria is more suitable.11 The NINDS-SPSP criteria was first published in July 1996, therefore clinical studies completed prior to this time would not have had access to an appropriate recruitment method. Background Mandatory exclusion criteria: Background The NINDS-SPSP clinical diagnosis criteria have been utilized in the prevalence study by Nath et al.8, which estimated the crude prevalence of PSP to be 6.5 per 100,000. A recent publication has suggested that the prevalence of PSP has been radically underestimated in clinical studies.12 Kovacs et al.13 identified two cases of pathologically confirmed PSP...